Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
- Address
- lock Available on a paid plan
Neurology and Pediatric Neuroimmunology
At Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego in Warsaw, clinical research in Nervous System Diseases focuses on conditions such as Acute Ischemic Stroke, high-risk transient ischemic attack, and Relapsing-Remitting Multiple Sclerosis. These studies are aimed at testing new treatment approaches, reducing the risk of serious neurological events, and better understanding therapy effects in children and adolescents.
- Acute Ischemic Stroke and high-risk transient ischemic attack: evaluating a new option to lower the chance of recurrent stroke
- Relapsing-Remitting Multiple Sclerosis: studying safety, tolerability, and how treatment behaves in younger patients
This area reflects a strong interest in improving outcomes for pediatric and adolescent patients with serious neurological disease.
Hematology and Blood Disorders
Research in Hemic and Lymphatic Diseases includes studies of Hemophilia, Severe Hemophilia A, Moderately Severe to Severe Hemophilia B, and Anemia associated with Chronic Kidney Disease. The trials are mainly designed to prevent bleeding, improve anemia management, and assess the effectiveness and safety of new therapies for children and adolescents.
- Hemophilia: examining medicines intended to reduce bleeding episodes and support prophylactic care
- Anemia in chronic kidney disease: evaluating a treatment to improve red blood cell levels in younger patients
These studies highlight a broad pediatric focus on better control of blood-related complications and long-term treatment safety.
Oncology and Pediatric Leukemia
The site is active in Neoplasms, with studies centered on Acute Myeloid Leukemia and Acute lymphoblastic leukemia. This research aims to improve survival, strengthen treatment responses, and support better outcomes for infants, children, and adolescents facing aggressive cancers.
- Acute Myeloid Leukemia: assessing whether treatment strategies can improve event-free survival and disease control
- Acute lymphoblastic leukemia in infants: studying ways to improve outcomes compared with earlier treatment results
The oncology portfolio at this hospital-based research site shows a clear emphasis on advancing pediatric leukemia care.
Endocrinology and Metabolic Disease Research
Clinical trials in Hormonal diseases and Nutritional and Metabolic Diseases include Type 1 diabetes mellitus and Idiopathic Growth Hormone Deficiency. These studies are exploring new ways to preserve insulin production, monitor long-term safety, and improve care for children and adolescents with chronic endocrine conditions.
- Type 1 diabetes mellitus: testing whether a new therapy can help preserve the body’s own insulin secretion
- Idiopathic growth hormone deficiency: evaluating long-term safety of a treatment used to support growth
This field combines treatment innovation with careful follow-up in pediatric hormone-related disorders.
Cardiovascular and Respiratory Medicine
Research in Cardiovascular Diseases and Respiratory Tract Diseases includes Heart Failure and Pulmonary Hypertension due to Left Heart Disease as well as Asthma and wheezing disorders. The trials are focused on improving symptom control, reducing complications, and evaluating whether new therapies can offer better results than current care.
- Heart Failure with pulmonary hypertension: studying a treatment intended to improve heart and lung vessel function
- Asthma and wheezing: assessing new options for reducing severe flare-ups in children
These studies show a practical focus on chronic diseases that can significantly affect daily life and long-term health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 47 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 2 | Unknown | 2022-12-06 | 2022-12-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.